血塞通注射液联合依达拉奉治疗急性脑梗死的Meta分析

Meta-analysis on the Treatment of Acute Cerebral Infarction(ACI) with Xuesaitong Injection Combined with Edaravone

目的系统评价依达拉奉联合血塞通治疗急性脑梗死日常生活能力(ADL)评分和安全性。方法计算机检索Cochrane Library,美国国立医学图书馆(Pub Med),中国生物医学文献数据库(CBM),中国期刊全文数据库(CNKI),维普中文科技期刊数据库(VIP),万方数据库等数据库,文种不限,检索时限均从各库建库起截止2014年8月31日,对纳入的随机对照试验进行方法学质量评价,并用Rev Man 5.3软件进行Meta分析。结果共纳入8个随机对照试验,研究结果显示,血塞通注射液联合依达拉奉组与单纯血塞通组相比,依达拉奉联合血塞通组日常生活能力评分均优于血塞通组[SMD=0.60,95%CI(0.37,0.83),P<0.00001];梗死后出血的发率[RR=1.67,95%CI(0.23,12.31),P=0.61]。结论依达拉奉联和血塞通治疗脑梗死能有效提高患者日常生活能力,并未增加梗死后出血的发生率。但由于样本量少,该结论还需更多设计合理、高质量、大样本的研究进一步验证。

Objective： To study the effect of Xuesaitong Injection combined with Edaravone on Barthel Index of the ability of daily life（ADL） and its safety in treating patients with acute cerebral infarction（ACI）. Methods：Data from the database foundation until August 31,2014 in Cochrane Library,Pub Med,CBM,CNKI,VIP and Wanfang Data was searched with computer. Randomized controlled trials（RCTs） of Xuesaitong Injection combined with Edaravone in any language were evaluated with the method of the quality and made a meta-analysis with Rev Man5.3 software. Results： 8 RCTs entered the inclusion criteria. The meta-analysis showed that compared with only Xuesaitong Injection,Xuesaitong injection combined with Edaravone can enhance the ability of daily life（ADL）[ SMD=0.60,95%CI（0.37,0.83）,P〈0.00001] and there exists no statistical difference in cecebral hemorrhage after infarction [RR =1.67,95% CI（0.23,12.31）,P = 0.61]. Conclusion： Xuesaitong Injection combined with Edaravone in treating patients with acute cerebral infaryion（ACI） can enhance the ability of daily life（Barthel Index）,and does not increase the occurrence of adverse events. But compared with the control group,it does not decrease the risk of cecebral hemorrhage after infarction. The quality of RCTs is low,so it needs more clinical trials of rational design and high quality study.